Filipe Gonçalves: Are DOACs Truly Pharmacokinetically Predictable or Simply Pharmacodynamically Forgiving?
Filipe Gonçalves, Docente at NOVA Medical School, shared a post on LinkedIn about a recent article by Joseph R. Shaw and Jack Ansell, published in Journal of Thrombosis and Haemostasis (JTH), adding:
”Are DOACs truly pharmacokinetically predictable or simply pharmacodynamically forgiving?
This article challenges a central assumption behind fixed-dose DOAC therapy.
Drug concentrations may vary considerably, while clinical effectiveness may persist because the pharmacodynamic response remains acceptable across a relatively broad exposure range.
It also highlights an important distinction between measuring drug concentration and measuring anticoagulant effect.
It also reminds us that commonly used thresholds such as 30 or 50 ng/mL are pragmatic decision cut-offs, not biologically validated safety boundaries.
A relevant perspective for pharmacology, laboratory medicine and urgent clinical decision-making.”
Title: A light in the dark—reframing direct oral anticoagulant pharmacokinetics and pharmacodynamics for near-patient decision-making
Authors: Joseph R. Shaw, Jack Ansell
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 11, 2026, 15:42Tareq Abadl: The Clinical Impact of Kell Alloimmunization
-
Nov 11, 2026, 15:30Alejandro González Veliz: Does PCI Change The Long-Term Outcome In Stable Coronary Artery Disease?
-
Nov 11, 2026, 15:25Preparing for the SoHO Regulation – EBA Board Convenes in Vienna – European Blood Alliance
-
Nov 11, 2026, 15:20Vaidehi Prasanth: IV Iron in Heart Failure – Exploring Hospitalisation Benefits vs. Infection Risk in Open Heart
-
Nov 11, 2026, 15:18Stefan Prendić: Can Algorithms Support Antibody Identification in Immunohematology?
-
Nov 11, 2026, 15:12Perioperative Challenges in Hemophilia Patients on Rebalancing Therapies
-
Nov 11, 2026, 15:03Maria Elisa Mancuso: World-Renowned Faculty and 33 Global Participants Unite at Hemophilia Academy 2026
-
Nov 11, 2026, 15:01Hassan Raza: The JAK2 V617F Revolution
-
Nov 11, 2026, 14:57Edward Lee Carter: Factor Xla Inhibition Enters Clinical Practice – FDA Approval of Asundexian